<!DOCTYPE html>
<html lang="en">
<head>
    <title>Tysabri Visual Aid</title>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
    <!--<meta name="viewport" content="width=device-width" />-->
    <!--<meta name="viewport" content="width=device-width, user-scalable=no" />-->
    <meta name="viewport" content="width=1024, initial-scale=1.0, user-scalable=no, maximum-scale=1.0"/>
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="format-detection" content="telephone=no">
    <link rel="apple-touch-icon-precomposed" href="apple-touch-icon-72x72.png" />
    <link rel="stylesheet" type="text/css" href="css/base.css"/>
	<link rel="stylesheet" type="text/css" href="css/welcome-standalone.css">
</head>
<body id="presentation" class="start home">
    <div id="container">
        <div id="outer_wrap">
            <div id="pres_wrapper">
                <div id="pres_scroller">
                    <div id="welcome" class="contents state-0">
                    </div>
                </div>
            </div>
        </div>
    </div>
    <section id="isi">
        <div class="contents ind-open">
            <div class="tap_div">
                <div class="grip"></div>
                <div class="info">Tap to <span class="collapse">collapse</span><span class="expand">expand</span></div>
            </div>
            <h3 class="indication open">Indication</h3>
            <p>TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The efficacy of TYSABRI beyond 2 years is unknown. Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate multiple sclerosis therapy. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.</p>
            <h3 class="open">Important Safety Information</h3>

            <div id="isi_wrapper">
                <div class="scroll-inner">
                    <p>WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY</p>
                    <p>TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI as monotherapy.</p>
                    <ul>
                        <li><span><strong>Because of the risk of PML, TYSABRI is available only through a special restricted distribution program called the TOUCH Prescribing Program. Under the TOUCH Prescribing Program, only prescribers, infusion centers, and pharmacies associated with infusion centers registered with the program are able to prescribe, infuse, or distribute the product. In addition, TYSABRI must be administered only to patients who are enrolled in and meet all the conditions of the TOUCH Prescribing Program.</strong></span></li>
                        <li><span><strong>Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.</strong></span></li>
                    </ul>
                </div>
                <div class="top_mask_ind_open"></div>
                <div class="top_mask_ind_closed"></div>
            </div>
        </div>
        <nav>
            <a href="#" onclick="top.navigateScene('TYS-IVA2-QA', 'Tysabri_ISI.pdf')" >isi</a>
            <a href="#" onclick="top.navigateScene('TYS-IVA2-QA', 'Tysabri_PI.pdf')">pi</a>
            <a href="#">ref</a>
        </nav>
    </section>
    <div class="grad-bak">
    </div>
    <img id="top-img" src="images/top-graphic.png" usemap="#sunmap" alt="sun" />
    
    <div id="isiPop" class="pop_up_window">
		<img src="images/button-close.png" id="close-img" />
        <div id="isiModalParent">
            <div id="isiModal">
                <div id="isiOuter">
                    <section id="isiOver">
                        <div><h1><a id="exit" onClick="top.navigateScene('TYS-Exit-Test-Black')" href="#">EXIT</a></h1></div>
                    </section>
                    <div id="signoff">
                        <div id="signoff_left">
                            <div id="biogen_logo"><img src="images/biogen_elan_isi_logos.gif" /></div>
                            <div id="tysabri_signoff">
                                TOUCH and TYSABRI are registered trademarks of Elan Pharmaceuticals, Inc.<br />
                                MS ACTIVESOURCE, BIOGEN IDEC and the BIOGEN IDEC logo are registered trademarks of Biogen Idec.<br />
                                ACTIVEACCESS and the ACTIVEACCESS logo are trademarks of Biogen Idec.<br />
                                The ELAN logo is a registered trademark of Elan Corporation, plc.<br />
                                All other trademarks are the property of their respective owners.<br />
								<span>&copy; 2012 Biogen Idec 12/12 3-8725-02</span>
                            </div>
                        </div>
                        <div id="tysabri_isi_logo"><img src="images/isi-head.png" /></div>
                    </div>
                </div>
            </div>
            <div class="reqIsiButtons">By tapping continue, I acknowledge that I have read and<br>understand the <b>TYSABRI Important Safety Information</b>.<br>
                <input type="image" src="images/button-cancel-quit.png" id="cancelquit">
                <input type="image" src="images/button-continue.png" id="continue" disabled="disabled">
            </div>
            <div class="fadeTop"></div>
            <div class="fadeBottom"></div>
        </div>
    </div>
    <script type="text/javascript" src="js/jquery.min.js"></script>
    <script type="text/javascript" src="js/iscroll.js"></script>
    <script type="text/javascript" src="js/scripts.js"></script>
    <script type="text/javascript" src="js/jquery.easing.1.3.js"></script>
    <script>
	
		
    	window.onload = function(){
    		var activeList = top.contactListIsActiveListEmpty();
			if (activeList){
				top.switchTarget();	
			}
			//top.switchTarget();
    		//console.log('executed switchTarget()');
    	}
    </script>
</body>
</html>